Cargando…

Introduction of biosimilar insulins in Europe

Regulatory approval of the first biosimilar insulin in Europe, LY2963016 insulin glargine (Abasaglar(®)), in 2014 expanded the treatment options available to people with diabetes. As biosimilar insulin products come to market, it is important to recognize that insulin products are biologicals manufa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Davies, M., Dahl, D., Heise, T., Kiljanski, J., Mathieu, C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Review Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5637898/ https://www.ncbi.nlm.nih.gov/pubmed/28608570 http://dx.doi.org/10.1111/dme.13400

Ejemplares similares

Biosimilar insulins: a European perspective
por: DeVries, J H, et al.
Publicado: (2015)

Biosimilar Oncology Drugs in Europe: Regulatory and Pharmacovigilance Considerations
por: Francescon, Sara, et al.
Publicado: (2016)

Policies for biosimilar uptake in Europe: An overview
por: Moorkens, Evelien, et al.
Publicado: (2017)

Ten years of biosimilar recombinant human growth hormone in Europe
por: Saenger, Paul
Publicado: (2017)

Ten years of biosimilars in Europe: development and evolution of the regulatory pathways
por: Schiestl, Martin, et al.
Publicado: (2017)

The Future of Biosimilar Insulins
por: Kim, Anne Park, et al.
Publicado: (2016)

Biosimilar insulin concepts
por: Bloomgarden, Zachary T.
Publicado: (2022)

Biosimilar insulins: guidance for data interpretation by clinicians and users
por: Heinemann, L., et al.
Publicado: (2015)

An Introduction to Biosimilars for the Treatment of Retinal Diseases: A Narrative Review
por: Hariprasad, Seenu M., et al.
Publicado: (2022)

An update on the clinical evidence that supports biosimilar approvals in Europe
por: Mielke, Johanna, et al.
Publicado: (2018)

Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications
por: Godman, Brian, et al.
Publicado: (2021)

Biosimilar and Follow-on Insulin: The Ins, Outs, and Interchangeability
por: White, John, et al.
Publicado: (2018)

Key drivers for market penetration of biosimilars in Europe
por: Rémuzat, Cécile, et al.
Publicado: (2017)

An Overview of Current Regulatory Requirements for Approval of Biosimilar Insulins
por: Heinemann, Lutz, et al.
Publicado: (2015)

Biosimilar Insulins – What a Clinician Needs to Know?
por: Ghosh, Sujoy, et al.
Publicado: (2019)

Corrigendum to “Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications”
por: Godman, Brian, et al.
Publicado: (2023)

Sustainability of Biosimilars in Europe: A Delphi Panel Consensus with Systematic Literature Review
por: Vulto, Arnold G., et al.
Publicado: (2020)

Biosimilar Insulins and Their Impact on Prices and Utilization of Insulins in Bulgaria
por: Tachkov, Konstantin, et al.
Publicado: (2021)

Etanercept biosimilars
por: Azevedo, Valderilio F., et al.
Publicado: (2014)

Introduction of Biosimilar Rituximab: A Hospital Perspective
por: Cheesman, Simon
Publicado: (2020)

How Similar Are Biosimilars? What Do Clinicians Need to Know About Biosimilar and Follow-On Insulins?
por: Triplitt, Curtis, et al.
Publicado: (2017)

Pharmacokinetic and pharmacodynamic bioequivalence of proposed biosimilar MYL‐1501D with US and European insulin glargine formulations in patients with type 1 diabetes mellitus
por: Heise, Tim, et al.
Publicado: (2019)

Production costs and potential prices for biosimilars of human insulin and insulin analogues
por: Gotham, Dzintars, et al.
Publicado: (2018)

Biosimilar insulins: Informed choice for South Asia
por: Kalra, Sanjay, et al.
Publicado: (2016)

Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience?
por: Mysler, Eduardo, et al.
Publicado: (2021)

The introduction of biosimilars of low molecular weight heparins in Europe: a critical review and reappraisal endorsed by the Italian Society for Haemostasis and Thrombosis (SISET) and the Italian Society for Angiology and Vascular Medicine (SIAPAV)
por: Imberti, Davide, et al.
Publicado: (2017)

Concepts and Challenges of Biosimilars in Breast Cancer: The Emergence of Trastuzumab Biosimilars
por: Uifălean, Alina, et al.
Publicado: (2018)

Impact of the mode of protraction of basal insulin therapies on their pharmacokinetic and pharmacodynamic properties and resulting clinical outcomes
por: Heise, Tim, et al.
Publicado: (2016)

Getting Familiar With Biosimilars
por: Mayden, Kelley D.
Publicado: (2016)

Use of Insulin Glargine 100 U/mL for the Treatment of Type 2 Diabetes Mellitus in East Asians: A Review
por: Hirose, Takahisa, et al.
Publicado: (2019)

Approval of the first biosimilar antibodies in Europe: A major landmark for the biopharmaceutical industry
por: Beck, Alain, et al.
Publicado: (2013)

Biosimilar insulins: An unavoidable option in South-East Asia
por: Kaduskar, Prashant Ulhas
Publicado: (2016)

Adalimumab Biosimilars in the Treatment of Rheumatoid Arthritis: A Systematic Review of the Evidence for Biosimilarity
por: Huizinga, Tom W. J., et al.
Publicado: (2020)

Safety of Insulin Lispro and a Biosimilar Insulin Lispro When Administered Through an Insulin Pump
por: Thrasher, James, et al.
Publicado: (2018)

Biosimilars in dermatology
por: Mazur, Małgorzata, et al.
Publicado: (2015)

Biosimilars: Beginning a Conversation
por: Campen, Christopher J., et al.
Publicado: (2016)

The arrival of biosimilar monoclonal antibodies in oncology: clinical studies for trastuzumab biosimilars
por: Barbier, Liese, et al.
Publicado: (2019)

Breaking Barriers With Basal Insulin Biosimilars in Type 2 Diabetes
por: Heller, Simon, et al.
Publicado: (2023)

The biosimilar pathway in the USA: An analysis of the innovator company and biosimilar company perspectives and beyond
por: Chang, Lin-Chau
Publicado: (2019)

Anti-Insulin Antibodies and Adverse Events with Biosimilar Insulin Lispro Compared with Humalog Insulin Lispro in People with Diabetes
por: Home, Philip, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_9k49ea5s1m9hsuebfel1217rji